Follistatin 344: Muscle Growth, Myostatin Inhibition, and Research Overview

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Follistatin 344 inhibits myostatin — the protein that limits muscle growth. Animal studies show dramatic muscle mass increases. Human data is limited. Typical research dose: 100 mcg/day for 10–30 days. Significant potential for muscle wasting conditions.

Understanding Myostatin and Muscle Growth Limits

Every person has a genetic ceiling on muscle mass, and a significant portion of that ceiling is determined by myostatin — a member of the TGF-beta superfamily that acts as a negative regulator of muscle growth. Individuals with naturally low myostatin levels develop extraordinary muscularity, as documented in several case reports of children with myostatin mutations who displayed remarkable muscle development from birth.

What Is Follistatin 344?

Follistatin 344 is one of several isoforms of follistatin, a glycoprotein produced primarily in the liver, gonads, and pituitary gland. The "344" designation refers to the 344-amino acid form, which is the predominant circulating isoform. As a myostatin inhibitor, it promotes muscle fiber hypertrophy and hyperplasia, reduces fat deposition, and may have effects on bone density and reproductive function.

Animal Research

The animal data on follistatin and myostatin inhibition is dramatic. Mice with follistatin overexpression develop muscle mass 2–3 times greater than wild-type mice. Gene therapy studies using follistatin-expressing viral vectors have demonstrated significant muscle mass increases in primates, driving interest in follistatin-based therapies for muscle wasting conditions like Duchenne muscular dystrophy, sarcopenia, and cachexia.

Research Peptide Use

Follistatin 344 is available as a research peptide. Typical protocols involve 100 mcg per day administered subcutaneously for 10–30 day cycles. Anecdotal reports describe significant muscle fullness and strength increases, though the quality of available follistatin 344 peptide products varies considerably.

Safety Considerations

The safety profile of exogenous follistatin 344 in humans is not well-characterized. Theoretical concerns include effects on reproductive function (follistatin regulates FSH through activin inhibition), potential promotion of cancer cell growth, and effects on bone metabolism. These concerns underscore the importance of caution and medical supervision when using this compound.